| Immunopathology of RSV: an updated review HC Bergeron, RA Tripp Viruses 13 (12), 2478, 2021 | 51 | 2021 |
| Diagnostic specificity of the African swine fever virus antibody detection enzyme‐linked immunosorbent assay in feral and domestic pigs in the United States HC Bergeron, PS Glas, KR Schumann Transboundary and emerging diseases 64 (6), 1665-1668, 2017 | 33 | 2017 |
| Respiratory syncytial virus (RSV) G protein vaccines with central conserved domain mutations induce CX3C-CX3CR1 blocking antibodies HC Bergeron, J Murray, AM Nuñez Castrejon, RM DuBois, RA Tripp Viruses 13 (2), 352, 2021 | 23 | 2021 |
| Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV) HC Bergeron, RA Tripp Expert Opinion on Investigational Drugs 31 (1), 23-29, 2022 | 19 | 2022 |
| Emerging small and large molecule therapeutics for respiratory syncytial virus HC Bergeron, RA Tripp Expert opinion on investigational drugs 29 (3), 285-294, 2020 | 16 | 2020 |
| Probenecid inhibits respiratory syncytial virus (RSV) replication J Murray, HC Bergeron, LP Jones, ZB Reener, DE Martin, FD Sancilio, ... Viruses 14 (5), 912, 2022 | 15 | 2022 |
| RSV replication, transmission, and disease are influenced by the RSV G protein HC Bergeron, RA Tripp Viruses 14 (11), 2396, 2022 | 10 | 2022 |
| Anti-G protein antibodies targeting the RSV G protein CX3C chemokine region improve the interferon response HC Bergeron, LM Kauvar, RA Tripp Therapeutic Advances in Infectious Disease 10, 20499361231161157, 2023 | 6 | 2023 |
| Microparticle RSV vaccines presenting the G protein CX3C chemokine motif in the context of TLR signaling induce protective Th1 immune responses and prevent pulmonary … TJ Powell, A Jacobs, J Tang, E Cardenas, N Palath, J Daniels, JG Boyd, ... Vaccines 10 (12), 2078, 2022 | 5 | 2022 |
| Influenza B virus (IBV) immune-mediated disease in C57BL/6 mice HC Bergeron, ZB Reneer, A Arora, S Reynolds, T Nagy, RA Tripp Vaccines 10 (9), 1440, 2022 | 4 | 2022 |
| Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine HC Bergeron, J Murray, MG Juarez, SJ Nangle, RM DuBois, RA Tripp Frontiers in Immunology 14, 1215323, 2023 | 2 | 2023 |
| Interferons—Implications in the Immune Response to Respiratory Viruses HC Bergeron, MR Hansen, RA Tripp Microorganisms 11 (9), 2179, 2023 | 1 | 2023 |
| Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein HC Bergeron, J Murray, A Arora, AM Nuñez Castrejon, RM DuBois, ... Viruses 15 (5), 1067, 2023 | 1 | 2023 |
| mRNA vaccines encoding influenza virus hemagglutinin (HA) elicits immunity in mice from influenza A virus challenge ZB Reneer, HC Bergeron, S Reynolds, E Thornhill-Wadolowski, L Feng, ... Plos one 19 (4), e0297833, 2024 | | 2024 |
| Blocking the RSV G Protein CX3C Chemokine Motif Protects Against RSV Disease HC Bergeron University of Georgia, 2023 | | 2023 |
| Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication (preprint) J Murray, HC Bergeron, LP Jones, T Chapman, ZB Reener, DE Martin, ... | | 2022 |
Ralph A. TrippProfessor, Georgia Research Alliance Eminent Scholar & Chair of Vaccine and Therapeutics DevelopmentVerified email at uga.edu
